C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
about
MET deregulation in breast cancerThe clinical and functional significance of c-Met in breast cancer: a reviewPrognostic significance of c-Met in breast cancer: a meta-analysis of 6010 casesSPSB1 may have MET its match during breast cancer recurrence.Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.Met and its ligand HGF are associated with clinical outcome in breast cancer.MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.Clinicopathological and prognostic significance of c-Met overexpression in breast cancer.Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways.Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China.Contribution of Adipose Tissue to Development of Cancer.Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling.
P2860
Q26781054-9AB8AF6C-E3A9-467D-A279-EE5A89CE0AE1Q28081415-50AA2860-98A9-486F-BFD2-2EB468235119Q28087523-F910C949-5C66-45F0-849D-12EAC113ACD7Q33876880-F7960266-C1D0-490B-AB3D-81BDD15EE725Q33880064-86AB420E-C03F-42AD-B4BC-4191610CE070Q35999644-598C990F-E6D0-457F-B6C5-70AD1FE48538Q36117367-74F5BE2F-1AF4-4716-8E5A-56F719464B08Q36723368-B1BAAE37-98B9-4F04-82E0-A40CD4C428D8Q37392930-B6CB939F-D60B-4605-9451-3351491A5FE9Q37702041-073BCE1D-B15D-48D1-975C-AD045AFAAE3EQ38236096-29FBDC96-2107-4FF4-9E05-3583DA4C1807Q38803271-0A681677-A186-4D4A-8D72-8D1C0E0EC243Q40858674-9AB6C5C7-383C-4835-99F2-9750F8094C2BQ41344857-35A9C633-F201-4D99-8BE9-A9ED00F5798EQ41647458-813F3CE7-CC49-4A3A-BAEA-03ED4CB5C7B4Q42027790-0B23D2DB-4C58-4B08-B27D-FF9E72A7C9CDQ42459082-F290328E-DE7E-4252-91FC-170CFD5BB9C0Q42480116-3B395EE3-4CEE-44BF-8754-A86B86335B1EQ48107341-47480400-4ADD-4334-B2A6-8040659888D1Q49164235-D508C4B9-B295-46C0-8E96-8A8ED6888C5FQ50026427-47496A16-63DC-4049-95D9-60744D92B16FQ52660791-4313AA63-353A-4134-A1C9-1077592AE4C0
P2860
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
@en
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
@nl
type
label
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
@en
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
@nl
prefLabel
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
@en
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
@nl
P2093
P2860
P50
P356
P1433
P1476
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
@en
P2093
Colan M Ho-Yen
Stephanie Kermorgant
P2860
P304
P356
10.1002/CNCR.28386
P407
P577
2013-10-21T00:00:00Z